Search

Munehisa A Yabuki

from Seattle, WA
Age ~54
Get Report
Related to:
Akiko Yabuki, 53Souma Yabuki, 22
Connected to:
Hitoshi Yabusaki, 67Alex Yabut, 65Anita I Yabut, 57Annie Yabut, 61Daniel R Yabut, 48Erna C Yabut, 56Ian Yabut, 28Jayson K Yabut, 54Jennifer A Yabut, 46Jerome F Yabut, 46

Munehisa Yabuki Phones & Addresses

  • 722 N 88Th St, Seattle, WA 98103 (206) 547-9935
  • 3634 Carr Rd, Seattle, WA 98103 (206) 547-9935
  • 1181 Whitney Ave, Hamden, CT 06517 (203) 865-6083

Work

Company: Omeros corporation 2011 Position: Senior scientist

Education

School / High School: Kurashiki Medical Center, Institute of Medical Science 1995 to 1999

Skills

Molecular Biology • Cell Culture • Drug Discovery • Protein Purification • Cell Biology • Assay Development • Biochemistry • Biotechnology • Western Blotting • Flow Cytometry • Protein Expression • Pcr • In Vitro • Immunology • Antibodies • Polymerase Chain Reaction

Industries

Biotechnology

Resumes

Resumes

Munehisa Yabuki Photo 1

Senior Scientist

View page
Location:
Seattle, WA
Industry:
Biotechnology
Work:
Omeros Corporation
Senior Scientist
University of Washington 2011 - 2011
Research Scientist Iii
Xori Corporation 2009 - 2011
Scientist
University of Washington 2005 - 2009
Acting Instructor
University of Washington 2000 - 2005
Senior Fellow
Education:
Kurashiki Medical Center, Institute of Medical Science 1995 - 1999
Okayama University 1995 - 1999
Doctorates, Doctor of Philosophy, Chemistry Okayama University 1989 - 1995
Master of Science, Masters, Bachelors, Bachelor of Science, Biotechnology
Skills:
Molecular Biology
Cell Culture
Drug Discovery
Protein Purification
Cell Biology
Assay Development
Biochemistry
Biotechnology
Western Blotting
Flow Cytometry
Protein Expression
Pcr
In Vitro
Immunology
Antibodies
Polymerase Chain Reaction

Publications

Us Patents

Inducible Mutagenesis Of Target Genes

View page
US Patent:
20100093033, Apr 15, 2010
Filed:
Jun 2, 2008
Appl. No.:
12/598031
Inventors:
Nancy Maizels - Seattle WA, US
W. Jason Cummings - Bellevue WA, US
Munehisa Yabuki - Seattle WA, US
Assignee:
University of Washington - Seattle WA
International Classification:
C12P 21/00
C12N 5/0781
US Classification:
435 691, 4353722
Abstract:
The present invention relates generally to mutagenesis of target genes that takes advantage of the natural mutagenic capabilities of B cells, and enhances those capabilities by bringing the process of diversification under control. The invention provides a method for rapidly and inducibly generating point mutations and other types of diversification in expressed genes, such as antibody genes. This method can be coupled with selection to identify B cell clones that produce, for example, antibodies of high affinity or specificity. The diversification process can be modulated, accelerated, halted, switched between methods of mutagenesis and the like. The modulation of diversification in accordance with the invention is both inducible and reversible. The invention provides a means of rapid and feasible development of a repertoire of variant immunoglobulins and other polypeptides.

Generation Of Anti-Fn14 Monoclonal Antibodies By Ex-Vivo Accelerated Antibody Evolution

View page
US Patent:
20120258121, Oct 11, 2012
Filed:
Mar 9, 2012
Appl. No.:
13/416752
Inventors:
John Benjamin Leppard - Mukilteo WA, US
Christi L. Wood - Snohomish WA, US
W. Jason Cummings - Bellevue WA, US
Munehisa Yabuki - Seattle WA, US
Nancy Maizels - Seattle WA, US
Daniel S. Allison - Lake Forest Park WA, US
Larry W. Tjoelker - Kirkland WA, US
Assignee:
Omeros Corporation - Seattle WA
International Classification:
C07K 16/28
A61P 35/04
A61P 35/00
C07K 17/02
A61K 39/395
US Classification:
4241721, 5303891, 5303873, 5303917
Abstract:
The present invention relates generally to anti-FN14 antibodies. In particular, the anti-FN14 antibodies described herein are useful for the treatment of diseases, such as a variety of cancers, associated with expression of FN14.

Anti-Fzd10 Monoclonal Antibodies And Methods For Their Use

View page
US Patent:
20130095104, Apr 18, 2013
Filed:
Aug 9, 2012
Appl. No.:
13/571151
Inventors:
W. Jason Cummings - Bellevue WA, US
Munehisa Yabuki - Seattle WA, US
John B. Leppard - Mukilteo WA, US
Christi L. Wood - Snohomish WA, US
Nancy Maizels - Seattle WA, US
Daniel S. Allison - Lake Forest Park WA, US
Larry W. Tjoelker - Kirkland WA, US
International Classification:
C07K 16/28
US Classification:
4241351, 5303879, 5303873, 5303917, 4241391, 435375, 4241331, 4241781
Abstract:
The present invention relates generally to anti-FZD10 antibodies and to methods of using anti-FZD10 antibodies. In particular, the anti-FZD10 antibodies described herein are useful for altering one or more of survival, replication, differentiation and epithelial-to-mesenchymal cell transition of embryonic stem cells and/or for the treatment of diseases, such as a variety of cancers, associated with expression of FZD10, including as stand-alone therapies and in combination therapies with other agents.

Composition And Method For Diversification Of Target Sequences

View page
US Patent:
20130261012, Oct 3, 2013
Filed:
Mar 13, 2013
Appl. No.:
13/802255
Inventors:
University of Washington Through Its Center for Commercialization - , US
John B. Leppard - Mukilteo WA, US
Nancy Maizels - Seattle WA, US
Larry W. Tjoelker - Kirkland WA, US
Christi L. Wood - Snohomish WA, US
Munehisa Yabuki - Seattle WA, US
Assignee:
University of Washington Through Its Center for Commercialization - Seattle WA
OMEROS CORPORATION - Seattle WA
International Classification:
C12N 15/10
US Classification:
506 9, 4353201, 4352523, 435349, 506 14, 435455, 506 26
Abstract:
The disclosure relates generally to the targeting of genes to, and their integration into, an immunoglobulin (antibody) heavy chain locus. In particular, the methods described herein contemplate replacing the single rearranged heavy chain V, D, and J genes of a B cell lymphoma such as DT40 with independently rearranged V-D-Jgenes of chicken, in a system for generating immunoglobulin diversity. Also contemplated is replacement of the chicken V-D-Jwith rearranged V-D-Jgenes of other vertebrates including human in a system for generating immunoglobulin diversity, with the exception of any substitution disclosed and claimed in PCT application WO 2009/029315 A2. Also described is construction of a diverse chicken immunoglobulin heavy chain VDJ library in DT40 by homologous gene replacement of the single endogenous rearranged VDJ gene with a chicken VDJ repertoire using the described targeting vectors.

Biomarker For Assessing The Risk Of Developing Acute Covid-19 And Post-Acute Covid-19

View page
US Patent:
20220308056, Sep 29, 2022
Filed:
Feb 4, 2022
Appl. No.:
17/665176
Inventors:
- Seattle WA, US
Thomas Dudler - Seattle WA, US
Nicholas James Lynch - Cambridge, GB
Hans-Wilhelm Schwaeble - Cambridge, GB
Kathleen Shaffer - Seattle WA, US
Munehisa Yabuki - Seattle WA, US
International Classification:
G01N 33/569
Abstract:
Disclosed herein are compositions, kits and methods for determining the concentration of fluid-phase MASP-2/C1-INH complex in a biological fluid, such as a biological fluid obtained from a subject infected with SARS-CoV-2. Also disclosed are methods of using said compositions, methods and kits for detection of MASP-2/C1-INH complex to determine the status of lectin pathway activation in a mammalian subject and thereby assess the risk of a subject that is or has been infected with SARS-CoV-2 for developing COVID-19-related ARDS or other poor outcome, or determine the need for treatment or efficacy of treatment of a subject in need thereof with a complement inhibitor such as a MASP-2 inhibitory agent.

Antibodies Specifically Binding To Masp-3 For The Treatment Of Various Diseases And Disorders

View page
US Patent:
20210275667, Sep 9, 2021
Filed:
Apr 27, 2021
Appl. No.:
17/241628
Inventors:
- Seattle WA, US
Gregory A. Demopulos - Mercer Island WA, US
Thomas Dudler - Bellevue WA, US
Larry W. Tjoelker - Kirkland WA, US
Christi L. Wood - Snohomish WA, US
Munehisa Yabuki - Seattle WA, US
International Classification:
A61K 39/395
C07K 16/40
C01F 17/206
B82Y 25/00
C09K 11/77
H01F 1/00
C12N 9/64
Abstract:
The present invention relates to MASP-3 inhibitory antibodies and compositions comprising such antibodies for use in inhibiting the adverse effects of MASP-3 dependent complement activation.

Methods Of Generating Bioactive Peptide-Bearing Antibodies And Compositions Comprising The Same

View page
US Patent:
20210079117, Mar 18, 2021
Filed:
Aug 4, 2020
Appl. No.:
16/984287
Inventors:
- Seattle WA, US
Patrick Gray - Seattle WA, US
Larry W. Tjoelker - Kirkland WA, US
Munehisa Yabuki - Seattle WA, US
International Classification:
C07K 16/40
C07K 14/81
C07K 16/00
Abstract:
In one aspect, the invention provides an isolated antibody, or antigen-binding fragment thereof, comprising a bioactive peptide amino acid sequence, wherein the bioactive peptide amino acid sequence is an inhibitor of the complement system and is fused to at least one of: (i) the amino terminal region of at least one of: a light chain variable region and/or a heavy chain variable region; or (ii) the carboxy terminal region of at least one of: a light chain constant region and/or a heavy chain constant region, wherein the antibody inhibits complement activation.

Antibodies Specifically Binding To Masp-3 For The Treatment Of Various Diseases And Disorders

View page
US Patent:
20200317510, Oct 8, 2020
Filed:
Jun 23, 2020
Appl. No.:
16/909578
Inventors:
- Seattle WA, US
Gregory A. Demopulos - Mercer Island WA, US
Thomas Dudler - Bellevue WA, US
Larry W. Tjoelker - Kirkland WA, US
Christi L. Wood - Snohomish WA, US
Munehisa Yabuki - Seattle WA, US
International Classification:
B82Y 25/00
C09K 11/77
C01F 17/206
H01F 1/00
Abstract:
The present invention relates to MASP-3 inhibitory antibodies and compositions comprising such antibodies for use in inhibiting the adverse effects of MASP-3 dependent complement activation.
Control profile
Munehisa A Yabuki from Seattle, WA, age ~54 Get Report